KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Convertible Debt (2016 - 2025)

Opko Health (OPK) has disclosed Convertible Debt for 13 consecutive years, with $85.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Convertible Debt fell 51.03% year-over-year to $85.0 million, compared with a TTM value of $85.0 million through Dec 2025, down 51.03%, and an annual FY2025 reading of $85.0 million, down 51.03% over the prior year.
  • Convertible Debt was $85.0 million for Q4 2025 at Opko Health, up from $82.7 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $323.1 million in Q1 2024 and bottomed at $77.2 million in Q1 2025.
  • Average Convertible Debt over 5 years is $179.2 million, with a median of $186.7 million recorded in 2021.
  • The sharpest move saw Convertible Debt skyrocketed 52.89% in 2024, then crashed 76.1% in 2025.
  • Year by year, Convertible Debt stood at $187.9 million in 2021, then grew by 11.94% to $210.4 million in 2022, then increased by 1.88% to $214.3 million in 2023, then fell by 19.0% to $173.6 million in 2024, then tumbled by 51.03% to $85.0 million in 2025.
  • Business Quant data shows Convertible Debt for OPK at $85.0 million in Q4 2025, $82.7 million in Q3 2025, and $80.5 million in Q2 2025.